More Anatara Lifesciences Ltd news
Anatara Lifesciences LtdASX: ANR

GaRP-IBS Clinical Trial Update

Dec 12, 2024 at 9:44 PM EST · Issued by Anatara Lifesciences Ltd

Filed with ASX · Dec 12, 2024 at 9:44 PM EST

On 6ix: 6ix.com/news/garp-ibs-clinical-trial-update

Anatara Lifesciences Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Anatara Lifesciences Ltd on 6ix

Story so far

  • GaRP-IBS Irritable Bowel Syndrome Clinical Trial UpdateOct 8, 2024
  • GaRP Irritable Bowel Syndrome Clinical Trial UpdateAug 30, 2024
  • Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2Feb 29, 2024

Earlier from Anatara Lifesciences

  • Share Purchase Plan Offer BookletNov 26, 2024
  • Successful Placement of $660k and Share Purchase PlanNov 15, 2024
  • Chair's Address to ShareholdersNov 14, 2024
  • Appendix 4C & Q1 FY25 Activities ReportOct 31, 2024
  • GaRP-IBS Irritable Bowel Syndrome Clinical Trial UpdateOct 7, 2024

Later from Anatara Lifesciences

  • Australian Patent Granted for GaRP ProductJan 28, 2025
  • Appendix 4D & Half Year Report 31 December 2024Feb 25, 2025
  • Phase II GaRP-IBS Trial & Anti-Obesity Project UpdatesMar 9, 2025
  • Phase II GaRP-IBS Trial Headline Analysis of ResultsApr 17, 2025
  • Funding Advance on R&D RefundApr 30, 2025
All Anatara Lifesciences news releases↗

Follow Anatara Lifesciences into a list and get an email when it puts out news.

Follow Anatara Lifesciences
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer